Literature DB >> 4741053

Mass spectrometric study of the distribution of cyclophosphamide in humans.

J H Duncan, O M Colvin, C Fenselau.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4741053     DOI: 10.1016/0041-008x(73)90151-8

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


× No keyword cloud information.
  6 in total

Review 1.  [Drug metabolism studies using mass spectrometry].

Authors:  G Spiteller; G Remberg
Journal:  Naturwissenschaften       Date:  1974-11

Review 2.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

3.  Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat.

Authors:  S Genka; J Deutsch; P L Stahle; U H Shetty; V John; C Robinson; S I Rapoport; N H Greig
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 4.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

5.  Difference in effect of single immunosuppressive agents (cyclophosphamide, CCNU, 5-FU) on peripheral blood immune cell parameters and central nervous system immunoglobulin synthesis rate in patients with multiple sclerosis.

Authors:  W W Shih; R W Baumhefner; W W Tourtellotte; C M Haskell; E L Korn; J L Fahey
Journal:  Clin Exp Immunol       Date:  1983-07       Impact factor: 4.330

6.  The kinetics of salivary elimination of cyclophosphamide in man.

Authors:  F D Juma; H J Rogers; J R Trounce
Journal:  Br J Clin Pharmacol       Date:  1979-11       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.